AlphAIAlphAI — Financial news for AI agents
tradingview.comOCT 131 min read

HC Wainwright & Co. reiterates Buy rating on Harmony Biosciences Hldgs, $55 price target

HC Wainwright & Co. reiterated a Buy rating on Harmony Biosciences Hldgs with a $55 price target, suggesting a 43.9% upside from the Oct 12 close of $38.23. The firm cited the CEO's biopharmaceutical experience and the company's focus on clinical execution and product pipeline expansion.

Original reporting
tradingview.com
Published Oct 13, 2026, 10:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 10:44 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
HC Wainwright & Co. reiterates Buy rating on Harmony Biosciences Hldgs, $55 price target — source image
Source · tradingview.com
Decision brief

The 30-second read

Low
01

Why it matters

Analyst coverage change could attract short-term interest but lacks substantive catalyst.

02

Market read

Rating reiteration provides modest upside potential but limited trading relevance.

03

What to watch

No recent clinical data or earnings release accompanies the rating.

Relevance 4/10Novelty 2/10Timing: same day

Background

Harmony Biosciences is a small-cap biotech focused on CNS therapies.

Market effects

Sector

May slightly lift sentiment in the biotech sector.

Regional

Limited to U.S. biotech investors.

Global

Minimal.

Counterpoint

What could challenge this read

The rating may be premature without new data; price could remain flat.

Key entities

  • Analyst Firm
    HC Wainwright & Co.

    Equity research firm that issued the rating.

  • Company
    Harmony Biosciences Holdings

    Biotech company receiving the rating.

Read at source← All news

Related articles

NOV 4
$HRMYMed

Harmony Biosciences 3Q 2026: Revenue $268.92M, Net income $48.2M, EPS $0.81— 10-Q Summary

Harmony Biosciences reported Q3 2026 revenue of $268.92M, up 12.3% YoY, but net income fell 5.2% to $48.2M and EPS declined 6.9% to $0.81. WAKIX revenue grew 12.3% in the quarter, driven by higher shipments and a price increase. The FDA accepted the Pitolisant GR NDA for review, with a target PDUFA date of April 1, 2027. Phase 3 trials for EPX-100 and Pitolisant HD are ongoing, with results expected in 2027. The company also began a Phase 1b study of BP-205.

tradingview.com1 min
NOV 4
$HRMYMedAI 8/10

Harmony Biosciences Reports Q3 Financial Results

Harmony Biosciences Holdings, Inc. (HRMY) filed an SEC Form 8-K — Results of Operations and Financial Condition. ‌ Exhibit 99.1 Harmony Biosciences Reports Q3 Financial Results On Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile ​ WAKIX ® Net Revenue in Q3 of $2

SEC EDGAR 8-K2 min